Serum PCSK9 is modified by interleukin-6 receptor antagonism in patients with hypercholesterolaemia following non-ST-elevation myocardial infarction

OBJECTIVE: It is unclear if activation of inflammatory pathways regulates proprotein convertase subtilisin-kexin type 9 (PCSK9) levels. APPROACH: We evaluated (1) the temporal course of serum PCSK9 during hospitalisation following acute coronary syndrome and associations with markers of inflammation...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Open Heart
Main Authors: Ueland, Thor, Kleveland, Ola, Michelsen, Annika E, Wiseth, Rune, Damås, Jan Kristian, Aukrust, Pål, Gullestad, Lars, Halvorsen, Bente, Yndestad, Arne
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2018
Assuntos:
Coronary Artery Disease
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6150185/
https://ncbi.nlm.nih.gov/pubmed/30258647
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/openhrt-2017-000765
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados